Background: Angiogenesis inhibitors have become an important therapeutic approach in the
treatment of hepatocellular carcinoma (HCC) patients. The therapeutic inhibition of …

Primary liver cancer, mainly consisting of hepatocellular carcinoma (HCC), is one of
common malignancies worldwide, and prevalent among the Chinese population. A …

ABSTRACT Angiogenesis and RAS/RAF/MEK/ERK pathway have been demonstrated to be
relevant in hepatocellular carcinoma (HCC). Sorafenib, an oral multikinase inhibitor with …

Background: Since the approval of sorafenib there have been numerous failures of new
agents in Phase III studies for treatment of advanced hepatocellular carcinoma (HCC) …

Management of advanced hepatocellular carcinoma (HCC), one of the most lethal cancers
worldwide, has presented a therapeutic challenge over past decades. Most patients with …

Cancer treatment has been revolutionized by the advent of new molecular targeted and
immunotherapeutic agents. Identification of the role of tumor angiogenesis changed the …

Hepatocellular carcinoma is the fastest growing cause of cancer related death globally.
Sorafenib, a multi-targeted kinase inhibitor, is the only drug proven to improve outcomes in …

Protein tyrosine kinases are enzymes that catalyze the transfer of phosphate groups from
ATP to tyrosine residues on other proteins as substrate. Phosphorylation at tyrosine residues …

Herein, we report a novel series of diaryl urea derivatives bearing a triazole moiety, from
which potent antitumor agents have been identified. With a modified triazole, most …

Purpose: To assess the safety and tolerability of the small-molecule allosteric MEK inhibitor
refametinib combined with sorafenib, in patients with advanced solid malignancies …